Clinical Trial Update: Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA

View source ↗

Summary

Clinical trial update reporting the completion and posting of results for a study evaluating compliance with Synagis (palivizumab) in premature infants with ges…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Synagis (palivizumab)

Snippet

Sponsor: Abbott | Conditions: Premature Infants | Status: COMPLETED | Results posted: 2012-08-21